片仔癀：中药经典名方西黄丸上市 布局肿瘤辅助治疗新赛道

Core Viewpoint - The launch of Xihuang Pill by Zhangzhou Pianzaihuang Pharmaceutical Co., Ltd. marks a significant step in the company's strategic layout in the field of tumor auxiliary treatment, enriching its product matrix centered around Pianzaihuang and Angong Niuhuang Pill [1][2] Group 1: Product Development - Xihuang Pill is based on traditional Chinese medicine and aims to inhibit tumor growth, regulate immune function, alleviate related symptoms, and reduce adverse reactions from chemotherapy and radiotherapy [1] - The product is developed using modern pharmaceutical technology while adhering to traditional preparation methods, ensuring quality upgrades [1] Group 2: Strategic Positioning - The launch of Xihuang Pill is part of Pianzaihuang's strategy to deepen its "one core, multiple products" layout, addressing unmet clinical needs through the development of advantageous varieties and new drug research [2] - The company has established a comprehensive traditional Chinese medicine product system covering various fields, including liver disease, cardiovascular health, anti-inflammation, and swelling reduction [2] Group 3: Market Promotion - Pianzaihuang has leveraged its channel network advantages, with Xihuang Pill already available in over 300 Pianzaihuang National Medicine Halls across the country [2] - The National Medicine Hall serves as a health service platform that combines traditional Chinese medicine culture dissemination, professional services, and product experience, facilitating convenient access to medications and promoting the rational use of Xihuang Pill [2] Group 4: Innovation and Tradition - The relaunch of Xihuang Pill represents a blend of traditional wisdom and modern technology, showcasing the company's commitment to innovation while honoring traditional Chinese medicine [2] - The company aims to continue driving high-quality development through innovation and meticulous manufacturing, revitalizing traditional Chinese medicine in the new era [2]